190 related articles for article (PubMed ID: 28715344)
21. Extreme restriction design as a method for reducing confounding by indication in pharmacoepidemiologic research.
Secrest MH; Platt RW; Dormuth CR; Chateau D; Targownik L; Nie R; Doyle CM; Dell'Aniello S; Filion KB
Pharmacoepidemiol Drug Saf; 2020 Jan; 29 Suppl 1():26-34. PubMed ID: 30628152
[TBL] [Abstract][Full Text] [Related]
22. Association between proton pump inhibitor use and risk of pneumonia in children: nationwide self-controlled case series study in Sweden.
Wang YH; Svanström H; Wintzell V; Ludvigsson JF; Pasternak B
BMJ Open; 2022 Apr; 12(4):e060771. PubMed ID: 35450917
[TBL] [Abstract][Full Text] [Related]
23. Proton pump inhibitor use and risk of community-acquired Clostridium difficile-associated disease defined by prescription for oral vancomycin therapy.
Dial S; Delaney JA; Schneider V; Suissa S
CMAJ; 2006 Sep; 175(7):745-8. PubMed ID: 17001054
[TBL] [Abstract][Full Text] [Related]
24. Proton Pump Inhibitor Use and the Risk of Chronic Kidney Disease.
Lazarus B; Chen Y; Wilson FP; Sang Y; Chang AR; Coresh J; Grams ME
JAMA Intern Med; 2016 Feb; 176(2):238-46. PubMed ID: 26752337
[TBL] [Abstract][Full Text] [Related]
25. Pharmacotherapy and the risk for community-acquired pneumonia.
Gau JT; Acharya U; Khan S; Heh V; Mody L; Kao TC
BMC Geriatr; 2010 Jul; 10():45. PubMed ID: 20604960
[TBL] [Abstract][Full Text] [Related]
26. Use of proton pump inhibitors and risk of iron deficiency: a population-based case-control study.
Tran-Duy A; Connell NJ; Vanmolkot FH; Souverein PC; de Wit NJ; Stehouwer CDA; Hoes AW; de Vries F; de Boer A
J Intern Med; 2019 Feb; 285(2):205-214. PubMed ID: 30141278
[TBL] [Abstract][Full Text] [Related]
27. Microbial evaluation of proton-pump inhibitors and the risk of pneumonia.
Meijvis SC; Cornips MC; Voorn GP; Souverein PC; Endeman H; Biesma DH; Leufkens HG; van de Garde EM
Eur Respir J; 2011 Nov; 38(5):1165-72. PubMed ID: 21478217
[TBL] [Abstract][Full Text] [Related]
28. Proton Pump Inhibitors and Risk of Acute and Chronic Kidney Disease: A Retrospective Cohort Study.
Hart E; Dunn TE; Feuerstein S; Jacobs DM
Pharmacotherapy; 2019 Apr; 39(4):443-453. PubMed ID: 30779194
[TBL] [Abstract][Full Text] [Related]
29. Factors associated with the initiation of proton pump inhibitors in corticosteroid users.
Munson JC; Wahl PM; Daniel G; Kimmel SE; Hennessy S
Pharmacoepidemiol Drug Saf; 2012 Apr; 21(4):366-74. PubMed ID: 22278844
[TBL] [Abstract][Full Text] [Related]
30. Effect of the clopidogrel-proton pump inhibitor drug interaction on adverse cardiovascular events in patients with acute coronary syndrome.
Bhurke SM; Martin BC; Li C; Franks AM; Bursac Z; Said Q
Pharmacotherapy; 2012 Sep; 32(9):809-18. PubMed ID: 22744772
[TBL] [Abstract][Full Text] [Related]
31. Risk of community-acquired pneumonia with outpatient proton-pump inhibitor therapy: a systematic review and meta-analysis.
Lambert AA; Lam JO; Paik JJ; Ugarte-Gil C; Drummond MB; Crowell TA
PLoS One; 2015; 10(6):e0128004. PubMed ID: 26042842
[TBL] [Abstract][Full Text] [Related]
32. No Significant Association Between Proton Pump Inhibitor Use and Risk of Stroke After Adjustment for Lifestyle Factors and Indication.
Nguyen LH; Lochhead P; Joshi AD; Cao Y; Ma W; Khalili H; Rimm EB; Rexrode KM; Chan AT
Gastroenterology; 2018 Apr; 154(5):1290-1297.e1. PubMed ID: 29269313
[TBL] [Abstract][Full Text] [Related]
33. Incidence of Campylobacter and Salmonella infections following first prescription for PPI: a cohort study using routine data.
Brophy S; Jones KH; Rahman MA; Zhou SM; John A; Atkinson MD; Francis N; Lyons RA; Dunstan F
Am J Gastroenterol; 2013 Jul; 108(7):1094-100. PubMed ID: 23588238
[TBL] [Abstract][Full Text] [Related]
34. Histamine H2-Blocker and Proton Pump Inhibitor Use and the Risk of Pneumonia in Acute Stroke: A Retrospective Analysis on Susceptible Patients.
Arai N; Nakamizo T; Ihara H; Koide T; Nakamura A; Tabuse M; Miyazaki H
PLoS One; 2017; 12(1):e0169300. PubMed ID: 28085910
[TBL] [Abstract][Full Text] [Related]
35. Meta-analysis: proton pump inhibitor use and the risk of community-acquired pneumonia.
Johnstone J; Nerenberg K; Loeb M
Aliment Pharmacol Ther; 2010 Jun; 31(11):1165-77. PubMed ID: 20222914
[TBL] [Abstract][Full Text] [Related]
36. Proton Pump Inhibitors and the Risk for Hospital-Acquired Clostridium difficile Infection.
Barletta JF; El-Ibiary SY; Davis LE; Nguyen B; Raney CR
Mayo Clin Proc; 2013 Oct; 88(10):1085-90. PubMed ID: 24012413
[TBL] [Abstract][Full Text] [Related]
37. Association between proton pump inhibitor use and gastric cancer: a population-based cohort study using two different types of nationwide databases in Korea.
Seo SI; Park CH; You SC; Kim JY; Lee KJ; Kim J; Kim Y; Yoo JJ; Seo WW; Lee HS; Shin WG
Gut; 2021 Nov; 70(11):2066-2075. PubMed ID: 33975868
[TBL] [Abstract][Full Text] [Related]
38. Proton pump Inhibitors and Risk of Enteric Infection in Inflammatory Bowel Disease: A Self-controlled Case Series.
Varma S; Trudeau SJ; Li J; Freedberg DE
Inflamm Bowel Dis; 2024 Jan; 30(1):38-44. PubMed ID: 36917215
[TBL] [Abstract][Full Text] [Related]
39. Proton Pump Inhibitors versus Histamine-2 Receptor Antagonists and Risk of Pneumonia in Patients with Acute Stroke.
Momosaki R; Yasunaga H; Matsui H; Fushimi K; Abo M
J Stroke Cerebrovasc Dis; 2016 May; 25(5):1035-1040. PubMed ID: 26853142
[TBL] [Abstract][Full Text] [Related]
40. Proton pump inhibitor use and risk of pneumonia: a self-controlled case series study.
Maret-Ouda J; Panula J; Santoni G; Xie S; Lagergren J
J Gastroenterol; 2023 Aug; 58(8):734-740. PubMed ID: 37314495
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
